Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients
Status:
Completed
Trial end date:
2020-06-24
Target enrollment:
Participant gender:
Summary
Niraparib (Zejula®)is extensively metabolized and eliminated primarily by hepatic and renal
pathways. The purpose of this study is to evaluate pharmacokinetics and safety of niraparib
in patients with moderate hepatic impairment, for the purpose of providing recommendations to
guide the initial dose and dose titration in this patient population.